Brilacidin - Innovation Pharmaceuticals

Drug Profile

Brilacidin - Innovation Pharmaceuticals

Alternative Names: Brilacidin tetrahydrochloride; Brilacidin-Ocular; Brilacidin-OM; Brilacidin-Otic; Defensin-mimetic - Innovation Pharmaceuticals; HDP-mimic - Innovation Pharmaceuticals; Host defense protein-mimic - Innovation Pharmaceuticals; PMX-30063

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PolyMedix
  • Developer Innovation Pharmaceuticals
  • Class Antibacterials; Peptidomimetics; Small molecules
  • Mechanism of Action Cell membrane permeability enhancers; Cell membrane structure modulators; Immunomodulators; Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Skin and soft tissue infections; Stomatitis; Ulcerative colitis
  • Preclinical Acne; Atopic dermatitis; Diabetic foot ulcer; Hidradenitis suppurativa; Ophthalmic infections; Otitis; Wounds
  • No development reported Intestinal infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Intestinal-infections in USA (PO)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Ulcerative-colitis in USA (Topical)
  • 26 Oct 2017 Innovation Pharmaceuticals plans to apply for FDA Breakthrough Therapy Designation for Stomatitis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top